Nicotinamide riboside (NAD+ precursor)

nad mitochondrial

Sold as a consumer product in 1 of 9 markets tracked; in clinical trials in 1.

5 randomized trials (262 people, 6-12 weeks). 1 improved its main endpoint, a blood or epigenetic marker; 4 found no effect. 1 further trial had no control group; it improved its main endpoint. 1 trial reported no pre-planned main endpoint.

Doses studied: 1000 mg/d NR plus 200 mg/d PT; 1000 mg/day; 250 mg NR + 50 mg PT.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (10)

T7 Lin 2025 Nicotinamide riboside supplementation combined with aerobic exercise training in hypertensive middle-aged and older adults: a pilot randomized clinical trial doi:10.1007/s11357-025-01815-2
T7 Martens 2026 Nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment: a randomized, double-blind, placebo-controlled pilot trial doi:10.1002/alz.71605
T7 Holmes 2026 NRPT supplementation in women undergoing the menopause transition: a pilot clinical trial doi:10.3389/fragi.2026.1773667
T7 Jensen 2022 Nicotinamide riboside and pterostilbene supplementation does not improve muscle stem cell recruitment after injury in elderly humans doi:10.1172/jci.insight.158314
T7 Orr 2024 A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment doi:10.1007/s11357-023-00999-9
T6 Dellinger 2017 NRPT increases NAD+ levels safely and sustainably in a randomized, double-blind, placebo-controlled trial of 120 healthy adults doi:10.1038/s41514-017-0016-9
T6 Heikkinen 2026 The Divergent Effects of Nicotinamide Riboside and High‐Intensity Exercise Training on Skeletal Muscle Epigenetic Aging doi:10.1111/acel.70638
T5 Reyna 2026 Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting doi:10.3389/fragi.2026.1652582
TX Biţă 2023 Nicotinamide Riboside, a Promising Vitamin B3 Derivative for Healthy Aging and Longevity: Current Evidence and Perspectives doi:10.3390/molecules28166078
TX Orlandi 2020 Nicotinamide, Nicotinamide Riboside and Nicotinic Acid, Emerging Roles in Replicative and Chronological Aging in Yeast doi:10.3390/biom10040604